ArticleFrontiers in oncology2022

Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells

Hongli Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.